Delayed graft function (DGF) complicates 20%-40% of deceased-donor kidney transplants and is associated with increased length of stay and subsequent allograft failure.
| INTRODUC TI ON
Delayed graft function (DGF) following kidney transplantation, defined as a need for dialysis in the first week posttransplant, occurs in 20%-40% of deceased donor kidney transplant recipients and increases the risk of short-and long-term morbidity. 1 Patients who
Accurate prediction of DGF risk for a particular allograft could influence organ allocation, patient counseling, and postoperative planning. Mitochondrial dysfunction, a reported surrogate of tissue health in ischemia-perfusion injury, might also be a surrogate for tissue health after organ transplantation. To understand the potential of mitochondrial membrane potential (MMP) in clinical decision-making, we analyzed whether lower MMP, a measure of mitochondrial dysfunction, was associated with DGF. In a prospective, single-center proof-of-concept study, we measured pretransplant MMP in 28 deceased donor kidneys and analyzed the association between MMP and DGF. We used hybrid registry-augmented regression to adjust for donor and recipient characteristics, minimizing overfitting by leveraging Scientific Registry of Transplant Recipients data. The range of MMP levels was 964-28 333 units.
Low-MMP kidneys (MMP<4000) were more likely from female donors (75% vs 10%, P = .002) and donation after cardiac death donors (75% vs 12%, P = .004). For every 10% decrease in MMP levels, there were 38% higher odds of DGF (adjusted odds ratio = 1.08 1.38 1.78 , P = .01). In summary, MMP might be a promising pretransplant surrogate for tissue health in kidney transplantation and, after further validation, could improve clinical decision-making through its independent association with DGF.
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basic (laboratory) research/science, cytotoxicity, donors and donation: deceased, kidney (allograft) function/dysfunction, kidney transplantation/nephrology, translational research/ science experience DGF are at an increased risk of acute rejection, graft failure, and posttransplant mortality. In models of cardiac and cerebral ischemia-reperfusion injury, mitochondrial dysfunction has proven to be a surrogate of tissue health. [8] [9] [10] [11] Cellular injury leads to loss of mitochondrial membrane potential (MMP), which leads to compromised ATP production and cell viability. 12 Despite increasing acceptance of MMP as an indicator of general cell health and viability and the clear need for a similar metric in the field of organ transplantation, its utility in assessing the tissue health of deceased donor organs has not been explored.
We hypothesized that MMP would be a surrogate for tissue health in donor organs and would correlate with an independent domain of DGF risk not captured by conventional clinical characteristics. We developed an assay for MMP measurement in kidney allograft biopsies that could be performed rapidly using minimal allograft tissue and analyzed whether loss of MMP was independently associated with DGF. 
| ME THODS

| Study population
| Donor and recipient data
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donor, wait-listed candidates, and transplant recipients in the United
States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere. 13 The Health Resources and Services Administration, US
Department of Health and Human Services provides oversight to
the activities of the OPTN and SRTR contractors.
Machine perfusion was used at the discretion of the procuring organ procurement organization and/or accepting surgeon for the preservation.
| Mitochondrial preparation and MMP measurement
Biopsy tissue was homogenized in cold extraction buffer using a hand-held tissue homogenizer. 
| MMP assay validation
A number of cell membrane permeable fluorescent dyes including JC-1 have been widely used in determining the MMP of cells. We applied the MMP assay to mitochondria extracted from human kidney biopsy samples based on our findings in 2 animal studies.
To determine whether JC-1 could also be used in determining MMP of extracted mitochondria and whether this assay pro- To determine whether MMP levels correlated with the ischemia time in cold-preserved organs, we extracted mitochondria from cold UW-preserved rat livers or kidneys at sequential time points and measured the MMP levels using a JC-1 fluorescent probe. The MMP levels of cold-preserved livers were significantly decreased at 48 hours and further declined in a time-dependent manner. The MMP levels of cold UW-preserved kidneys remained the same at 72 hours, but significantly decreased at 96 hours after cold preservation.
| Posttransplant outcomes
Our primary outcome of interest was DGF, defined as a need for dialysis within 1 week posttransplant. Both DGF status and serum creatinine at posttransplant day 5 were manually abstracted from recipients' electronic medical records.
| Statistical analysis
We analyzed the association between pretransplant MMP level and risk of DGF. We also compared MMP levels by postoperative renal function (DGF vs no DGF) using Kruskal-Wallis equality-ofpopulations rank test.
| Posttransplant delayed graft function
We explored the independent association between MMP level and DGF using logistic regression, adjusting for donor characteristics (age, race, cause of death, diabetes, hypertension, and creatinine), recipient characteristics (age, gender, race, previous kidney transplant, BMI, primary diagnosis, hepatitis C status, insurance, renal replacement therapy time), and organ/transplant characteristics (cold ischemia time, donation following cardiac death status, pump use, zero mismatch, donor/recipient weight ratio, organ share type).
| Hybrid registry-augmented regression
We performed hybrid registry-augmented regression, a method developed and previously described by our group, to leverage the large 
| Stepwise association of MMP and DGF
In order to explore the stepwise association between MMP and graft function, we subdivided patients who did not experience DGF (non- Confidence intervals are reported as per the method of Louis and Zeger. 15 All analyses were performed using Stata 14.1/MP for Windows (College Station, TX).
| RE SULTS
| Study population
Of the 28 patients included in final analysis, 8 (29%) had MMP <4000 units ("low MMP") and 20 (71%) had MMP of at least 4000
("high MMP"). Compared to kidneys with high MMP, kidneys with low MMP were more likely to be from female donors (75% vs 10%, P = .002), from donors after cardiac death (DCD; 88% vs 25%, P = .004), to receive ex vivo machine perfusion (50% vs 5%, P = .01), and to be transplanted into female recipients (0% vs 50%, P = .02) (Table 1) . Kidneys with low MMP and kidneys with high MMP had similar cold ischemia time, HLA mismatching, PRA, and frequency of national or regional sharing (Table 1) . At postoperative day 5, 4 patients had DGF, 11 had SGF, and 13 had IGF. Donors with lower MMP levels (≤4000 RFU) were more likely to be female (75% vs 10%, P = .002) than donors with higher MMP levels, but did not differ significantly in age, creatinine, cause of death, or frequency of diabetes or hypertension. Recipients of kidneys with lower MMP levels were less likely to be female (0% vs 50%, P = .02) than recipients of kidneys with higher MMP levels, but were otherwise similar (Table 1) . Transplants of kidneys with lower MMP levels were more likely to be DCD (88% vs 25%, P = .004) and were more likely to have received machine perfusion (50% vs 5%, P = .01) but had similar cold ischemia time, number of HLA mismatches, donor/ recipient weight ratio, frequency of national or regional sharing, and recipient sensitization (Table 1) .
| MMP levels and DGF
Higher MMP levels were associated with lower odds of de- 
| D ISCUSS I ON
In this single-center proof-of-concept study of mitochondrial membrane potential analysis in 28 pretransplant donor kidney biopsies, we found that MMP levels were an independent predictor of DGF risk and that an MMP threshold of 4000 differentiated patients with DGF from those with immediate graft function. For every 10% decrease in pretransplant MMP, recipients had a 38% higher risk of DGF (P = .01), even after adjusting for donor, recipient, and organ/ transplant characteristics. Since MMP levels can be rapidly determined and are available pretransplant, our findings suggest that MMP levels might be a promising surrogate of tissue health of donor kidneys, and pending further validation, potentially serve as an independent predictor of DGF risk following transplantation. Our findings that MMP was associated with risk of DGF are consistent with previous literature linking MMP levels with tissue function in models of cardiac and cerebral ischemia and reperfusion, as well as septic acute kidney injury 16, 17 and drug-related toxicity.
TA B L E 1 Patient characteristics by pretransplant MMP levels
18,19
MMP has also been explored as a method of testing the effects of cooling and rewarming on renal cells in animal models. 20 These findings further support the use of MMP in renal transplantation, an
as-yet unexplored application of this marker of tissue function that warrants further study. Notably, mitochondrial function has been noted to differ by sex, including in particular tissues, [21] [22] [23] [24] and the proportion of female and male donor kidneys in the high and low MMP groups differed in this study. However, differences in MMP by sex have not been specifically studied and should be investigated.
Limitations of this study include a pilot, proof-of-concept sample size, which will require further validation in larger populations.
However, we were able to leverage risk adjustment using the SRTR data set, allowing us to test whether MMP risk prediction was independent of 21 other donor, recipient, and transplant characteristics. Our findings using registry-augmented regression analysis suggest that MMP measures risk of DGF beyond that predicted by other variables currently available in the national transplant data set.
However, additional validation in larger sample sizes is indicated to confirm these findings. Another limitation of the study is potential imprecision in the quantity of mitochondria in each sample. Since the assay is standardized per microgram of protein, variability in the results could theoretically arise from variation in the precise degree to which a fraction of protein from stroma lacking mitochondria was included in each biopsy. However, such variation would bias our findings toward the null, suggesting that differences in the MMP levels between groups might be even larger than those found in this study. Additionally, we recognize that this MMP assay will need to be standardized for each organ type, because it is unknown whether there are organ-specific differences in the density of mitochondria per microgram of protein.
In conclusion, we found that MMP independently predicted DGF among our sample of kidney transplant recipients. The findings of this pilot study suggest future work to be done to investi- 
